



Dr Wiseman David

Synechion, Inc. 6757 Arapaho Rds., Suite 711-238 75248 Dallas, TX USA 19 729 315 596 19 729 315 476 david.wiseman@adhesions.org

Topic : Adhesion Prevention

Authors and addresses : Wiseman, DM,¹ Meidler, R,² Lyahovetsky, Y, ² Kurman, E,² Horn, S.² Nur, I.²

1 Synechion, Inc., Dallas, TX
2 Omrix Biopharmaceuticals Ltd., Nes-Ziona, Israel

Correspondence to:
Dr. D. Wiseman
Synechion, Inc.
PMB 238, 6757 Arapaho, Suite 711, Dallas, Texas, 75248

Presenting Authors : Dr. D. Wiseman

Evaluation of a tranexamic acid supplemented fibrin sealant (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding, and in a model with two surgical loci

A rabbit uterine model was used to compare the efficacy of a tranexamic acid-supplemented fibrin sealant (Adhexil) & established devices. To separately identify any remote effect of Adhexil, a dual model (DUAL) added a cecal/sidewall injury.

In non-bleeding (NB) & bleeding (BL) model variants, animals (n=5/gp) were randomized to Control Adhexil, Seprafilm (SF), SprayGel (SG) or INTERCEED (INT - BL only) groups. In the DUAL model Adhexil was placed at both, neither or either loci. Adhesions were scored 13-16 d later.

Adhexil significantly reduced the adhesion extent (15 + 7%; 15 + 4%) versus Controls (74 + 13%; 78 + 9%) in the BL & NB models. SF (39 + 17%; 34 + 14%) or SG (61 + 18%; 43 + 14%, N=4) reduced adhesions non-significantly. In the BL model, INT (48 + 15%) only effected a modest reduction in extent.

In the DUAL model, Adhexil reduced selectively the extent & incidence of adhesions at the uterus & sidewall. The absolute and comparative performance of Adhexil in an established model of adhesions, together in the presence of bleeding justifies its further investigation as an adhesion barrier.